Delivery Order SPE2DB24D1021-SPE2DB25FEVEK

Award Date 3/24/25
Potential Completion Date 3/25/25
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for $1,891.59 and was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of AMOX-CLAV 875-125 MG TABLET 100S, a type of antibiotic medication, and has an ultimate completion date of March 25, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. Amerisourcebergen holds a significant $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,668.84 delivery order contract is for the procurement of AMOX-CLAV 875-125 MG TABLET 20S, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of May 12, 2023. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,479.55 firm fixed-price delivery order is for AMOX-CLAV 875-125 MG TABLET 20S, with a period of performance through January 6, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range...
This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,385.08, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The IDC, valued at $999,999,999, serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $9,849.54 for the supply of AMOX-CLAV 875-125 MG TABLET UD 100S, a generic pharmaceutical product. The contract has an ultimate completion date of March 20, 2025 and is a Firm Fixed Price contract. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $1,517.51, is a delivery order for the supply of AMOX-CLAV 250-125 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 14, 2024 and is a firm fixed-price contract. This award is not designated as a set-aside contract....
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a $3,865.19 Firm Fixed Price delivery order (SPE2DB24FM1YS) issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of 4,565,766,152 units of Amox-Clav 875-125 mg tablets, with a completion date of September 12, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 between Amerisourcebergen and the DLA Troop Support...
This federal contract award, valued at $1,184.03, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
The U.S. government agency Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The $7,032.05 contract is for the delivery of 20-count blister packs of Amox-Clav 875-125 mg tablets. This delivery order falls under an existing $999,999,999.00 indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp as a single-award vehicle. The IDC serves as...
This federal contract award is for a Delivery Order (DO) valued at $5,976.76, issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of AMOX-CLAV 400-57 MG TAB CHEW 20S, a medical product. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB24D1021
    Indefinite Delivery Contract
  • SPE2DB24D1021-SPE2DB25FEVEK
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,767.98, is a Firm Fixed Price Delivery Order for the supply of AMOX-CLAV 875-125 MG TABLET UD 100S. The contract has a completion date of March 25, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award was not designated with a set-aside requirement, indicating open competition.

Generated 6/29/25, 12:57 AM